The estrogen receptor pathway in rhabdomyosarcoma: A role for estrogen receptor-β in proliferation and response to the antiestrogen 4′OH-tamoxifen

Cancer Research

Volumn 68, Issue 9, 2008, Pages 3476-3485

  Greenberg, Joshua A ^a,b   Somme, Stig ^a,b   Russnes, Hege E ^d   Durbin, Adam D ^a,b   Malkin, David ^a,b,c,e  

^a Hospital for Sick Children

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

^e Division of Haematology/Oncology   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; 4' HYDROXY TAMOXIFEN; ADENOSINE DIPHOSPHATE RIBOSE; ANTIESTROGEN; CASPASE 3; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; RNA; UNCLASSIFIED DRUG; ESR1 PROTEIN, HUMAN; TAMOXIFEN;

APOPTOSIS; ARTICLE; CELL GROWTH; CELL PROLIFERATION; CELL VIABILITY; CELLULAR DISTRIBUTION; COLONY FORMATION; CONTROLLED STUDY; DRUG INHIBITION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RHABDOMYOSARCOMA; SIGNAL TRANSDUCTION; CELL CULTURE; DRUG EFFECT; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; PHYSIOLOGY; TISSUE DISTRIBUTION;

APOPTOSIS; CELL PROLIFERATION; ESTRADIOL; ESTROGEN ANTAGONISTS; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; RHABDOMYOSARCOMA; SIGNAL TRANSDUCTION; TAMOXIFEN; TISSUE DISTRIBUTION; TUMOR CELLS, CULTURED; TUMOR STEM CELL ASSAY;

EID: 44849095864     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-3046     Document Type: Article

References (48)

1. Pappo AS. Rhabdomyosarcoma and other soft tissue sarcomas in children. Curr Opin Oncol 1996;8:311-6.
2. Pizzo PA, Poplack DG. Principles and Practice of Pediatric Oncology. 5th ed. Philadelphia: Lippincott Williams & Wilkins, 2006; p. xiv, 1780.
3. Voute PA, Barrett A, Stevens CG, Caron HN. Cancer in Children: Clinical Management. 5th ed. Oxford University Press; 2005. p. 448.
4. Anderson J, Gordon A, McManus A, Shipley J, Pritchard-Jones K. Disruption of imprinted genes at chromosome region 11p15.5 in paediatric rhabdomyosarcoma. Neoplasia 1999;1:340-8.
5. Baserga R, Peruzzi F, Reiss K. The IGF-1 receptor in cancer biology. Int J Cancer 2003;107:873-7.
6. De Giovanni C, Melani C, Nanni P, et al. Redundancy of autocrine loops in human rhabdomyosarcoma cells: induction of differentiation by suramin. Br J Cancer 1995;72:1224-9.
7. Gee MF, Tsuchida R, Eichler-Jonsson C, Das B, Baruchel S, Malkin D. Vascular endothelial growth factor acts in an autocrine manner in rhabdomyosarcoma cell lines and can be inhibited with all-transretinoic acid. Oncogene 2005;24:8025-37.
8. Maloney EK, McLaughlin JL, Dagdigian NE, et al. An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation. Cancer Res 2003;63:5073-83.
9. Schweigerer L, Neufeld G, Mergia A, Abraham JA, Fiddes JC, Gospodarowicz D. Basic fibroblast growth factor in human rhabdomyosarcoma cells: implications for the proliferation and neovascularization of myoblast-derived tumors. Proc Natl Acad Sci U S A 1987;84:842-6.
10. Xia SJ, Pressey JG, Barr FG. Molecular pathogenesis of rhabdomyosarcoma. Cancer Biol Ther 2002;1:97-104.
11. Zhan S, Shapiro DN, Helman LJ. Activation of an imprinted allele of the insulin-like growth factor II gene implicated in rhabdomyosarcoma. J Clin Invest 1994;94:445-8.
12. Kinzbrunner B, Ritter S, Domingo J, Rosenthal CJ. Remission of rapidly growing desmoid tumors after tamoxifen therapy. Cancer 1983;52:2201-4.
13. McAdam WA, Goligher JC. The occurrence of desmoids in patients with familial polyposis coli. Br J Surg 1970;57:618-31.
14. Ohashi T, Shigematsu N, Kameyama K, Kubo A. Tamoxifen for recurrent desmoid tumor of the chest wall. Int J Clin Oncol 2006;11:150-2.
15. Sportiello DJ, Hoogerland DL. A recurrent pelvic desmoid tumor successfully treated with tamoxifen. Cancer 1991;67:1443-6.
16. Ishizuka M, Hatori M, Dohi O, et al. Expression profiles of sex steroid receptors in desmoid tumors. Tohoku J Exp Med 2006;210:189-98.
17. Deyrup AT, Tretiakova M, Montag AG. Estrogen receptor-β expression in extraabdominal fibromatoses: an analysis of 40 cases. Cancer 2006;106:208-13.
18. Nilsson S, Makela S, Treuter E, et al. Mechanisms of estrogen action. Physiol Rev 2001;81:1535-65.
19. Tsai MJ, O'Malley BW. Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu Rev Biochem 1994;63:451-86.
20. Enmark E, Pelto-Huikko M, Grandien K, et al. Human estrogen receptor β-gene structure, chromosomal localization, and expression pattern. J Clin Endocrinol Metab 1997;82:4258-65.
21. Gosden JR, Middleton PG, Rout D. Localization of the human oestrogen receptor gene to chromosome 6q24-q27 by in situ hybridization. Cytogenet Cell Genet 1986;43:218-20.
22. Dougherty SM, Mazhawidza W, Bohn AR, et al. Gender difference in the activity but not expression of estrogen receptors α and β in human lung adenocarcinoma cells. Endocr Relat Cancer 2006;13:113-34.
23. Martin LA, Pancholi S, Chan CM, et al. The anti-oestrogen ICI 182,780, but not tamoxifen, inhibits the growth of MCF-7 breast cancer cells refractory to long-term oestrogen deprivation through down-regulation of oestrogen receptor and IGF signalling. Endocr Relat Cancer 2005;12:1017-36.
24. Strom A, Hartman J, Foster JS, Kietz S, Wimalasena J, Gustafsson JA. Estrogen receptor β inhibits 17β-estradiol-stimulated proliferation of the breast cancer cell line T47D. Proc Natl Acad Sci U S A 2004;101:1566-71.
25. Wakeling AE. Dukes M, Bowler J. A potent specific pure antiestrogen with clinical potential. Cancer Res 1991;51:3867-73.
26. Shen SS, Smith CL, Hsieh JT, et al. Expression of estrogen receptors-a and -h in bladder cancer cell lines and human bladder tumor tissue. Cancer 2006;106:2610-6.
27. McPherson SJ, Ellem SJ, Simpson ER, Patchev V, Fritzemeier KH, Risbridger GP. Essential role for estrogen receptor β in stromal-epithelial regulation of prostatic hyperplasia. Endocrinology 2007;148:566-74.
28. Takahashi Y, Perkins SN, Hursting SD, Wang TT. 17β-estradiol differentially regulates androgen-responsive genes through estrogen receptor-β-and extracellular-signal regulated kinase-dependent pathways in LNCaP human prostate cancer cells. Mol Carcinog 2007;46:117-29.
29. Ohshiro K, Rayala SK, Williams MD, Kumar R, El-Naggar AK. Biological role of estrogen receptor β in salivary gland adenocarcinoma cells. Clin Cancer Res 2006;12:5994-9.
30. Batistatou A, Stefanou D, Goussia A, Arkoumani E, Papavassiliou AG, Agnantis NJ. Estrogen receptor β (ERβ) is expressed in brain astrocytic tumors and declines with dedifferentiation of the neoplasm. J Cancer Res Clin Oncol 2004;130:405-10.
31. Campbell-Thompson M, Lynch IJ, Bhardwaj B. Expression of estrogen receptor (ER) subtypes and ERβ isoforms in colon cancer. Cancer Res 2001;61:632-40.
32. Gruvberger-Saal SK, Bendahl PO, Saal LH, et al. Estrogen receptor {β} expression is associated with tamoxifen response in ER{α}-negative breast carcinoma. Clin Cancer Res 2007;13:1987-94.
33. Zacharin M, Waters K, Chow CW, Crock P, McKelvie P. Recurrent rhabdomyosarcoma after 25 years: a possible association with estrogen and progestogen therapy. J Pediatr Hematol Oncol 1997;19:477-81.
34. Gottardis MM, Robinson SP, Jordan VC. Estradiol-stimulated growth of MCF-7 tumors implanted in athymic mice: a model to study the tumoristatic action of tamoxifen. J Steroid Biochem 1998;30:311-4.
35. Goldstein SR, Siddhanti S, Ciaccia AV, Plouffe L, Jr. A pharmacological review of selective oestrogen receptor modulators. Hum Reprod Update 2000;6:212-24.
36. Chagin AS, Karimian E, Zaman F, Takigawa M, Chrysis D, Savendahl L. Tamoxifen induces permanent growth arrest through selective induction of apoptosis in growth plate chondrocytes in cultured rat metatarsal bones. Bone 2007;40:1415-24.
37. Wu X, Ahn EY, McKenna MA, Yeo H, McDonald JM. Fas binding to calmodulin regulates apoptosis in osteoclasts. J Biol Chem 2005;280:29964-70.
38. Wilcken N, Tattersall MH. Endocrine therapy for desmoid tumors. Cancer 1991;68:1384-8.
39. Barkhem T, Carlsson B, Nilsson Y, Enmark E, Gustafsson J, Nilsson S. Differential response of estrogen receptor α and estrogen receptor β to partial estrogen agonists/antagonists. Mol Pharmacol 1998;54:105-12.
40. Dauvois S, White R, Parker MG. The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling. J Cell Sci 1993;106:1377-88.
41. Lee H, Bai W. Regulation of estrogen receptor nuclear export by ligand-induced and p38-mediated receptor phosphorylation. Mol Cell Biol 2002;22:5835-45.
42. Metzger D, Ali S, Bornert JM, Chambon P. Characterization of the amino-terminal transcriptional activation function of the human estrogen receptor in animal and yeast cells. J Biol Chem 1995;270:9535-42.
43. Zheng A, Kallio A, Harkonen P. Tamoxifen-induced rapid death of MCF-7 breast cancer cells is mediated via ERK signaling and can be abrogated by estrogen. Endocrinology 2007;148:2764-77.
44. Rodriguez-Galindo C, Hill DA, Onyekwere O, et al. Neonatal alveolar rhabdomyosarcoma with skin and brain metastases. Cancer 2001;92:1613-20.
45. Parham DM. Appearances may be deceiving: does aggressive histology correlate with behavior of infantile sarcomas? Pediatr Dev Pathol 2002;5:513-4.
46. Arts J, Kuiper GG, Janssen JM, et al. Differential expression of estrogen receptors α and β mRNA during differentiation of human osteoblast SV-HFO cells. Endocrinology 1997;138:5067-70.
47. Sorensen MG, Henriksen K, Dziegiel MH, Tanko LB, Karsdal MA. Estrogen directly attenuates human osteoclastogenesis, but has no effect on resorption by mature osteoclasts. DNA Cell Biol 2006;25:475-83.
48. Andersen J, Orntoft T, Skorvgaard Poulsen H. Semiquantitative oestrogen receptor assay in formalin-fixed paraffin sections of human breast cancer tissue using monoclonal antibodies. Br J Cancer 1986;53:691-4.